XOMA CORPORATION (XOMA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

XOMA CORPORATION (XOMA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Resignation of Senior Vice President, Research and Development and Chief Medical Officer

On November 11, 2016, Dr. Paul Rubin, M.D., tendered his resignation as Senior Vice President, Research and Development and Chief Medical Officer of XOMA Corporation (“XOMA”). Dr. Rubin’s resignation is effective as of Friday, November 18, 2016. Dr. Rubin’s responsibilities will be assumed by Dr. Patrick J. Scannon, M.D., Ph.D., XOMA’s Executive Vice President and Chief Scientific Officer, and other current members of XOMA’s clinical, regulatory and medical teams.

 

About XOMA CORPORATION (XOMA)